Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Cytokinetics: Phase 3 Trial for Tirasemtiv About to Begin with Topline Results Possible in 2H, 2016; Successful Outcome Could Make the Stock a Homerun (CYTK, $6.35, Buy, For Paid Subscribers)

Introduction

Management has recently provided details of the upcoming phase 3 trial of tirasemtiv in the treatment of ALS; this trial…
Read more…

Cytokinetics: Takeaways from Recent R&D Day and Reiteration of Buy (CYTK, $6.14, Buy)

Investment Overview

I find the recent stock weakness in Cytokinetics perplexing. The Company has a market value of about $300 million…
Read more…